These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 28715695)
21. Overexpression of microRNA-133b is associated with the increased survival of patients with hepatocellular carcinoma after curative hepatectomy: Involvement of the EGFR/PI3K/Akt/mTOR signaling pathway. Wang X; Zeng J; Wang L; Zhang X; Liu Z; Zhang H; Dong J Oncol Rep; 2017 Jul; 38(1):141-150. PubMed ID: 28586051 [TBL] [Abstract][Full Text] [Related]
22. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Janku F; Kaseb AO; Tsimberidou AM; Wolff RA; Kurzrock R Oncotarget; 2014 May; 5(10):3012-22. PubMed ID: 24931142 [TBL] [Abstract][Full Text] [Related]
23. The Translational Bridge between Inflammation and Hepatocarcinogenesis. Gufler S; Seeboeck R; Schatz C; Haybaeck J Cells; 2022 Feb; 11(3):. PubMed ID: 35159342 [TBL] [Abstract][Full Text] [Related]
24. Hydrogen sulfide promotes autophagy of hepatocellular carcinoma cells through the PI3K/Akt/mTOR signaling pathway. Wang SS; Chen YH; Chen N; Wang LJ; Chen DX; Weng HL; Dooley S; Ding HG Cell Death Dis; 2017 Mar; 8(3):e2688. PubMed ID: 28333142 [TBL] [Abstract][Full Text] [Related]
25. Exploring the molecular mechanism of hepatitis virus inducing hepatocellular carcinoma by microarray data and immune infiltrates analysis. Zhang YZ; Zeb A; Cheng LF Front Immunol; 2022; 13():1032819. PubMed ID: 36439183 [TBL] [Abstract][Full Text] [Related]
26. Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease. Bortolami M; Kotsafti A; Cardin R; Farinati F J Viral Hepat; 2008 Jul; 15(7):515-22. PubMed ID: 18331250 [TBL] [Abstract][Full Text] [Related]
27. The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism. Tian LY; Smit DJ; Jücker M Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768977 [TBL] [Abstract][Full Text] [Related]
28. Viral hepatitis markers in liver tissue in relation to serostatus in hepatocellular carcinoma. Hernandez BY; Zhu X; Kwee S; Chan OT; Tsai N; Okimoto G; Horio D; McGlynn KA; Altekruse S; Wong LL Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):2016-23. PubMed ID: 23983238 [TBL] [Abstract][Full Text] [Related]
29. Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center. Franssen B; Alshebeeb K; Tabrizian P; Marti J; Pierobon ES; Lubezky N; Roayaie S; Florman S; Schwartz ME Ann Surg; 2014 Oct; 260(4):650-6; discussion 656-8. PubMed ID: 25203882 [TBL] [Abstract][Full Text] [Related]
30. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227 [TBL] [Abstract][Full Text] [Related]
31. Immunohistochemistry panel segregates molecular types of hepatocellular carcinoma in Brazilian autopsy cases. Felipe-Silva A; Wakamatsu A; Dos Santos Cirqueira C; Alves VA World J Gastroenterol; 2016 Jul; 22(27):6246-56. PubMed ID: 27468214 [TBL] [Abstract][Full Text] [Related]
32. KIFC3 regulates progression of hepatocellular carcinoma via EMT and the AKT/mTOR pathway. Lu S; Liu Y; Tian S; He Y; Dong W Exp Cell Res; 2023 May; 426(1):113564. PubMed ID: 36948354 [TBL] [Abstract][Full Text] [Related]
33. COPS8 promotes hepatocellular carcinoma progression through the PI3K/AKT/mTOR pathway. Yan X; Li Z; Tian Q; Zhang Y Asian J Surg; 2024 Jun; 47(6):2947-2949. PubMed ID: 38431475 [No Abstract] [Full Text] [Related]
34. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Ladu S; Calvisi DF; Conner EA; Farina M; Factor VM; Thorgeirsson SS Gastroenterology; 2008 Oct; 135(4):1322-32. PubMed ID: 18722373 [TBL] [Abstract][Full Text] [Related]
35. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway. Zhang M; Liu S; Chua MS; Li H; Luo D; Wang S; Zhang S; Han B; Sun C Cell Death Dis; 2019 Aug; 10(8):612. PubMed ID: 31406106 [TBL] [Abstract][Full Text] [Related]
36. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Grabinski N; Ewald F; Hofmann BT; Staufer K; Schumacher U; Nashan B; Jücker M Mol Cancer; 2012 Nov; 11():85. PubMed ID: 23167739 [TBL] [Abstract][Full Text] [Related]
37. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice. Wang C; Cigliano A; Jiang L; Li X; Fan B; Pilo MG; Liu Y; Gui B; Sini M; Smith JW; Dombrowski F; Calvisi DF; Evert M; Chen X Hepatology; 2015 Jan; 61(1):200-13. PubMed ID: 25145583 [TBL] [Abstract][Full Text] [Related]
38. Expressions of MiR-132 in patients with chronic hepatitis B, posthepatitic cirrhosis and hepatitis B virus-related hepatocellular carcinoma. Liu B; Yang XF; Liang XP; Wang L; Shao MM; Han WX; Wu YH Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8431-8437. PubMed ID: 30556884 [TBL] [Abstract][Full Text] [Related]
39. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways. Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344 [TBL] [Abstract][Full Text] [Related]
40. Effects of orexin A on glucose metabolism in human hepatocellular carcinoma in vitro via PI3K/Akt/mTOR-dependent and -independent mechanism. Liu Y; Zhao Y; Guo L Mol Cell Endocrinol; 2016 Jan; 420():208-16. PubMed ID: 26549689 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]